Myeloid-specific Rictor Deletion Induces M1 Macrophage Polarization and Potentiates in Vivo Pro-inflammatory Response to Lipopolysaccharide
Overview
Affiliations
The phosphoinositide-3-kinase (PI3K)/protein kinase B (Akt) axis plays a central role in attenuating inflammation upon macrophage stimulation with toll-like receptor (TLR) ligands. The mechanistic target of rapamycin complex 2 (mTORC2) relays signal from PI3K to Akt but its role in modulating inflammation in vivo has never been investigated. To evaluate the role of mTORC2 in the regulation of inflammation in vivo, we have generated a mouse model lacking Rictor, an essential mTORC2 component, in myeloid cells. Primary macrophages isolated from myeloid-specific Rictor null mice exhibited an exaggerated response to TLRs ligands, and expressed high levels of M1 genes and lower levels of M2 markers. To determine whether the loss of Rictor similarly affected inflammation in vivo, mice were either fed a high fat diet, a situation promoting chronic but low-grade inflammation, or were injected with lipopolysaccharide (LPS), which mimics an acute, severe septic inflammatory condition. Although high fat feeding contributed to promote obesity, inflammation, macrophage infiltration in adipose tissue and systemic insulin resistance, we did not observe a significant impact of Rictor loss on these parameters. However, mice lacking Rictor exhibited a higher sensitivity to septic shock when injected with LPS. Altogether, these results indicate that mTORC2 is a key negative regulator of macrophages TLR signalling and that its role in modulating inflammation is particularly important in the context of severe inflammatory challenges. These observations suggest that approaches aimed at modulating mTORC2 activity may represent a possible therapeutic approach for diseases linked to excessive inflammation.
Zheng X, Xu Z, Xu L, Wang L, Qin S, Ying L Inflammation. 2024; 48(1):165-180.
PMID: 38767784 DOI: 10.1007/s10753-024-02037-y.
Loss of Macrophage mTORC2 Drives Atherosclerosis via FoxO1 and IL-1β Signaling.
Zhang X, Evans T, Chen S, Sergin I, Stitham J, Jeong S Circ Res. 2023; 133(3):200-219.
PMID: 37350264 PMC: 10527041. DOI: 10.1161/CIRCRESAHA.122.321542.
Murokawa H, Egusa K, Shibutani S, Iwata H J Vet Med Sci. 2023; 85(7):772-780.
PMID: 37225457 PMC: 10372260. DOI: 10.1292/jvms.22-0504.
Adipose tissue macrophages as potential targets for obesity and metabolic diseases.
Li X, Ren Y, Chang K, Wu W, Griffiths H, Lu S Front Immunol. 2023; 14:1153915.
PMID: 37153549 PMC: 10154623. DOI: 10.3389/fimmu.2023.1153915.
Targeting the biology of aging with mTOR inhibitors.
Mannick J, Lamming D Nat Aging. 2023; 3(6):642-660.
PMID: 37142830 PMC: 10330278. DOI: 10.1038/s43587-023-00416-y.